Results and Impact of the Follow-Up of the NeoALTTO Trial

January 21, 2014
Carlos L. Arteaga, MD

Carlos L. Arteaga, MD, discusses the results and impact of the four-year follow-up analysis of the NeoALTTO trial, which analyzed patients with HER2-positive breast cancer.

Clinical Pearls

Carlos L. Arteaga, MD, professor of medicine and cancer biology, Vanderbilt-Ingram Cancer Center, discusses the results and impact of the four-year follow-up analysis of the NeoALTTO trial, which analyzed patients with HER2-positive breast cancer.

  • The NeoALTTO trial set out to determine whether the higher pathologic complete response (pCR) rate achieved with lapatinib plus trastuzumab translated into better overall survival or event-free survival
  • The hazard for event-free survival was 65%-70% lower for patients who achieved pCR than for those who did not
  • This trial is important because the FDA now allows for the approval of novel therapies following testing in the adjuvant setting